Senda Biosciences, a Cambridge, Mass.-based company that harnesses the molecular interactions between humans, plants, and bacteria to develop new types of medicines, raised a $55m Series B extension financing, bringing its total Series B funding to $98m and total funding raised to date to $143m.
Flagship Pioneering, Senda’s founder, participated along with new investors including Longevity Vision Fund, Terra Magnum Capital Partners, Mayo Clinic, Partners Investment and Mint Venture Partners. Current investors Alexandria Venture Investments and State of Michigan Retirement System also participated.
Proceeds from the financing will be used to advance the development of the company’s platform and its therapeutic programs into clinical trials.
Led by Guillaume Pfefer, Ph.D., Chief Executive Officer, and Scott Plevy, M.D., Chief Scientific Officer, Senda Biosciences is systematically harnessing the molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines. The company’s platform enables the deployment of proteins or genetic material throughout the body, tunable modulation of the immune system, and precise intervention at the point of interaction between human and non-human species.
FinSMEs
12/06/2021